BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pichichero ME, Khan MN, Xu Q. Next generation protein based Streptococcus pneumoniae vaccines. Hum Vaccin Immunother 2016;12:194-205. [PMID: 26539741 DOI: 10.1080/21645515.2015.1052198] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Principi N, Esposito S. Development of pneumococcal vaccines over the last 10 years. Expert Opinion on Biological Therapy 2017;18:7-17. [DOI: 10.1080/14712598.2018.1384462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
2 Khan MN, Xu Q, Pichichero ME. Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection. Infect Immun 2017;85:e00530-16. [PMID: 27895132 DOI: 10.1128/IAI.00530-16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
3 Huang J, Luo S, Huang M, Zhang T, Min Z, Liu C, Zhang Q, Yang J, Min X. Protection against fatal pneumonia through mucosal and subcutaneous immunization with the pneumococcal SP0148 protein. Microb Pathog 2019;129:206-12. [PMID: 30772476 DOI: 10.1016/j.micpath.2019.02.018] [Reference Citation Analysis]
4 Janesch P, Rouha H, Badarau A, Stulik L, Mirkina I, Caccamo M, Havlicek K, Maierhofer B, Weber S, Groß K, Steinhäuser J, Zerbs M, Varga C, Dolezilkova I, Maier S, Zauner G, Nielson N, Power CA, Nagy E. Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies. Virulence 2018;9:1521-38. [PMID: 30289054 DOI: 10.1080/21505594.2018.1520545] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Wouters I, Desmet S, Van Heirstraeten L, Herzog SA, Beutels P, Verhaegen J, Goossens H, Van Damme P, Malhotra-Kumar S, Theeten H; NPcarriage Study Group. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveill 2020;25. [PMID: 32046817 DOI: 10.2807/1560-7917.ES.2020.25.5.1900303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ekinci E, Desmet S, Van Heirstraeten L, Mertens C, Wouters I, Beutels P, Verhaegen J, Malhotra-Kumar S, Theeten H; NPcarriage Group. Streptococcus pneumoniae Serotypes Carried by Young Children and Their Association With Acute Otitis Media During the Period 2016-2019. Front Pediatr 2021;9:664083. [PMID: 34291017 DOI: 10.3389/fped.2021.664083] [Reference Citation Analysis]
7 Dorosti H, Eslami M, Nezafat N, Fadaei F, Ghasemi Y. Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy. Mol Cell Probes 2019;48:101446. [PMID: 31520715 DOI: 10.1016/j.mcp.2019.101446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Smith AM, Huber VC. The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza. Viral Immunol 2018;31:159-73. [PMID: 29148920 DOI: 10.1089/vim.2017.0138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Wagner A, Weinberger B. Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. Front Immunol 2020;11:717. [PMID: 32391017 DOI: 10.3389/fimmu.2020.00717] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
10 Karner A, Gesslbauer B, Spreitzer A, Almer J, Smidt M, Schüler W, Fartmann B, Zimmermann W, Meinke A, Kungl AJ. Profiling the Membrane and Glycosaminoglycan-Binding Proteomes of Moraxella catarrhalis. J Proteome Res 2016;15:3055-97. [DOI: 10.1021/acs.jproteome.6b00187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Stanek RJ, Norton NB, Mufson MA. A 32-Year Study of the Effect of Pneumococcal Vaccines on Invasive Streptococcus pneumoniae Disease. The American Journal of the Medical Sciences 2016;352:563-73. [DOI: 10.1016/j.amjms.2016.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 Bewersdorf JP, Grandgirard D, Koedel U, Leib SL. Novel and preclinical treatment strategies in pneumococcal meningitis. Curr Opin Infect Dis 2018;31:85-92. [PMID: 29095719 DOI: 10.1097/QCO.0000000000000416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Shekhar S, Khan R, Schenck K, Petersen FC. Intranasal Immunization with the Commensal Streptococcus mitis Confers Protective Immunity against Pneumococcal Lung Infection. Appl Environ Microbiol 2019;85:e02235-18. [PMID: 30683742 DOI: 10.1128/AEM.02235-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Moens L, Hermand P, Wellens T, Wuyts G, Derua R, Waelkens E, Ysebaert C, Godfroid F, Bossuyt X. Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization. Hum Vaccin Immunother 2018;14:1234-42. [PMID: 29400602 DOI: 10.1080/21645515.2018.1430541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Feng S, Xiong C, Wang G, Wang S, Jin G, Gu G. Exploration of Recombinant Fusion Proteins YAPO and YAPL as Carrier Proteins for Glycoconjugate Vaccine Design against Streptococcus pneumoniae Infection. ACS Infect Dis 2020;6:2181-91. [PMID: 32687317 DOI: 10.1021/acsinfecdis.0c00260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Beitelshees M, Hill A, Li Y, Chen M, Ahmadi MK, Smith RJ Jr, Andreadis ST, Rostami P, Jones CH, Pfeifer BA. Antigen delivery format variation and formulation stability through use of a hybrid vector. Vaccine X 2019;1:100012. [PMID: 31384734 DOI: 10.1016/j.jvacx.2019.100012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Patil SU, Shreffler WG. Novel vaccines: Technology and development. J Allergy Clin Immunol 2019;143:844-51. [PMID: 29970235 DOI: 10.1016/j.jaci.2018.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
18 Wang Y, Wen Z, Pan X, Briles DE, He Y, Zhang JR. Novel Immunoprotective Proteins of Streptococcus pneumoniae Identified by Opsonophagocytosis Killing Screen. Infect Immun 2018;86:e00423-18. [PMID: 29891544 DOI: 10.1128/IAI.00423-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Pichichero ME. Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vaccines 2017;16:1181-90. [PMID: 29130395 DOI: 10.1080/14760584.2017.1393335] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
20 Voß F, Kohler TP, Meyer T, Abdullah MR, van Opzeeland FJ, Saleh M, Michalik S, van Selm S, Schmidt F, de Jonge MI, Hammerschmidt S. Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation. Front Immunol 2018;9:2405. [PMID: 30405609 DOI: 10.3389/fimmu.2018.02405] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
21 Akbari E, Negahdari B, Faraji F, Behdani M, Kazemi-Lomedasht F, Habibi-Anbouhi M. Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae. Biotechnol Rep (Amst) 2019;24:e00385. [PMID: 31763198 DOI: 10.1016/j.btre.2019.e00385] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Esposito S, Principi N European Society Of Clinical Microbiology And Infectious Diseases Escmid Vaccine Study Group Evasg. Strategies to develop vaccines of pediatric interest. Expert Rev Vaccines 2017;16:175-86. [PMID: 27653455 DOI: 10.1080/14760584.2017.1237875] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
23 Almudevar A, Pichichero ME. Modeling specific antibody responses to natural immunization to predict a correlate of protection against infection before commencing a clinical vaccine trial. Hum Vaccin Immunother 2017;13:2316-21. [PMID: 28892455 DOI: 10.1080/21645515.2017.1329064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
24 O'Grady KF, Cripps AW, Grimwood K. Paediatric and adult bronchiectasis: Vaccination in prevention and management. Respirology 2019;24:107-14. [PMID: 30477047 DOI: 10.1111/resp.13446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Chan WY, Entwisle C, Ercoli G, Ramos-Sevillano E, McIlgorm A, Cecchini P, Bailey C, Lam O, Whiting G, Green N, Goldblatt D, Wheeler JX, Brown JS. A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge. Infect Immun 2019;87:e00846-18. [PMID: 30530620 DOI: 10.1128/IAI.00846-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Koh SH, Shin SG, Andrade MJ, Go RH, Park S, Woo CH, Lim JH. Long pentraxin PTX3 mediates acute inflammatory responses against pneumococcal infection. Biochem Biophys Res Commun 2017;493:671-6. [PMID: 28864415 DOI: 10.1016/j.bbrc.2017.08.133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ayoola MB, Shack LA, Nakamya MF, Thornton JA, Swiatlo E, Nanduri B. Polyamine Synthesis Effects Capsule Expression by Reduction of Precursors in Streptococcus pneumoniae. Front Microbiol 2019;10:1996. [PMID: 31555234 DOI: 10.3389/fmicb.2019.01996] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Chan W, Entwisle C, Ercoli G, Ramos-sevillano E, Mcilgorm A, Cecchini P, Bailey C, Lam O, Whiting G, Green N, Goldblatt D, Wheeler JX, Brown JS, Pirofski L. Corrected and Republished from: “A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge”. Infect Immun 2022;90:e00846-18a. [DOI: 10.1128/iai.00846-18a] [Reference Citation Analysis]
29 Xu Q, Pryharski K, Pichichero ME. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model. Vaccine 2017;35:337-44. [PMID: 27919628 DOI: 10.1016/j.vaccine.2016.11.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
30 Weinberger B. Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. Immun Ageing 2021;18:38. [PMID: 34627326 DOI: 10.1186/s12979-021-00249-6] [Reference Citation Analysis]
31 Hu Y, Park N, Seo KS, Park JY, Somarathne RP, Olivier AK, Fitzkee NC, Thornton JA. Pneumococcal surface adhesion A protein (PsaA) interacts with human Annexin A2 on airway epithelial cells. Virulence 2021;12:1841-54. [PMID: 34233589 DOI: 10.1080/21505594.2021.1947176] [Reference Citation Analysis]
32 Oesterreich S, Lindemann M, Goldblatt D, Horn PA, Wilde B, Witzke O. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine 2020;38:3339-50. [PMID: 32178906 DOI: 10.1016/j.vaccine.2020.02.088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
33 Mendy AL, Agbla SC, Odutola AA, Antonio M, Greenwood BM, Sutherland JS, Ota MOC. Kinetics of antibodies against pneumococcal proteins and their relationship to nasopharyngeal carriage in the first two months of life. PLoS One 2017;12:e0185824. [PMID: 28982123 DOI: 10.1371/journal.pone.0185824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Sohail I, Ghosh S, Mukundan S, Zelewski S, Khan MN. Role of Inflammatory Risk Factors in the Pathogenesis of Streptococcus pneumoniae. Front Immunol 2018;9:2275. [PMID: 30333833 DOI: 10.3389/fimmu.2018.02275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
35 Luck JN, Tettelin H, Orihuela CJ. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. Front Cell Infect Microbiol 2020;10:613287. [PMID: 33425786 DOI: 10.3389/fcimb.2020.613287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Hsu CF, Hsiao CH, Tseng SF, Chen JR, Liao YJ, Chen SJ, Lin CS, Sytwu HK, Chuang YP. PrtA immunization fails to protect against pulmonary and invasive infection by Streptococcus pneumoniae. Respir Res 2018;19:187. [PMID: 30253765 DOI: 10.1186/s12931-018-0895-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang Y, Xia L, Wang G, Lu H, Wang H, Luo S, Zhang T, Gao S, Huang J, Min X. Subcutaneous immunization with the fusion protein ΔA146Ply-SP0148 confers protection against Streptococcus pneumoniae infection. Microb Pathog 2021;162:105325. [PMID: 34848296 DOI: 10.1016/j.micpath.2021.105325] [Reference Citation Analysis]
38 Pichichero ME. Ten-Year Study of Acute Otitis Media in Rochester, NY. Pediatr Infect Dis J 2016;35:1027-32. [PMID: 27182898 DOI: 10.1097/INF.0000000000001216] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
39 Papastamatiou T, Routsias JG, Koutsoni O, Dotsika E, Tsakris A, Spoulou V. Evaluation of Protective Efficacy of Selected Immunodominant B-Cell Epitopes within Virulent Surface Proteins of Streptococcus pneumoniae. Infect Immun 2018;86:e00673-17. [PMID: 29263108 DOI: 10.1128/IAI.00673-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 García-Suárez MDM, González-Rodríguez I, Cima-Cabal MD, Yuste JE, Vazquez F, Santiago E. Identification of Pneumococcal Serotypes by PCR-Restriction Fragment Length Polymorphism. Diagnostics (Basel) 2019;9:E196. [PMID: 31752204 DOI: 10.3390/diagnostics9040196] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]